Terms: = Sarcomas AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
17 results:
1. A Case Study of a Rare Undifferentiated Spindle Cell Sarcoma of the Penis: Establishment and Characterization of Patient-Derived Models.
Sousa ACDS; Fernandes BLNC; da Silva JPA; Stevanato Filho PR; Coimbra LBCT; de Oliveira Beserra A; Alvarenga AL; Maida G; Guimaraes CT; Nakamuta IM; Marchi FA; Alves C; Lichtenfels M; de Farias CB; Kupper BEC; Costa FD; de Mello CAL; Carraro DM; Torrezan GT; Lopes A; Dos Santos TG
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674359
[TBL] [Abstract] [Full Text] [Related]
2. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical development of a chimeric antigen receptor T cell therapy targeting fgfr4 in rhabdomyosarcoma.
Tian M; Wei JS; Shivaprasad N; Highfill SL; Gryder BE; Milewski D; Brown GT; Moses L; Song H; Wu JT; Azorsa P; Kumar J; Schneider D; Chou HC; Song YK; Rahmy A; Masih KE; Kim YY; Belyea B; Linardic CM; Dropulic B; Sullivan PM; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL; Orentas RJ; Cheuk AT; Khan J
Cell Rep Med; 2023 Oct; 4(10):101212. PubMed ID: 37774704
[TBL] [Abstract] [Full Text] [Related]
4. fgfr4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.
Sullivan PM; Kumar R; Li W; Hoglund V; Wang L; Zhang Y; Shi M; Beak D; Cheuk A; Jensen MC; Khan J; Dimitrov DS; Orentas RJ
Mol Cancer Ther; 2022 Oct; 21(10):1608-1621. PubMed ID: 35877472
[TBL] [Abstract] [Full Text] [Related]
5. Molecular mechanisms of Guadecitabine induced fgfr4 down regulation in alveolar rhabdomyosarcomas.
Darvishi E; Slemmons K; Wan Z; Mitra S; Hou X; Hugues Parmentier J; Eddie Loh YH; Helman LJ
Neoplasia; 2020 Jul; 22(7):274-282. PubMed ID: 32464274
[TBL] [Abstract] [Full Text] [Related]
6. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
Ramadan F; Fahs A; Ghayad SE; Saab R
Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
[TBL] [Abstract] [Full Text] [Related]
7. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in fgfr4 tyrosine kinase using molecular modeling strategies.
Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
[TBL] [Abstract] [Full Text] [Related]
8. Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.
Yang X; Huang WT; Wu HY; He RQ; Ma J; Liu AG; Chen G
Oncol Rep; 2019 Apr; 41(4):2241-2253. PubMed ID: 30816547
[TBL] [Abstract] [Full Text] [Related]
9. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract] [Full Text] [Related]
10. Update on molecular findings in rhabdomyosarcoma.
El Demellawy D; McGowan-Jordan J; de Nanassy J; Chernetsova E; Nasr A
Pathology; 2017 Apr; 49(3):238-246. PubMed ID: 28256213
[TBL] [Abstract] [Full Text] [Related]
11. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
[TBL] [Abstract] [Full Text] [Related]
12. fgfr4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells.
Wachtel M; Rakic J; Okoniewski M; Bode P; Niggli F; Schäfer BW
Int J Cancer; 2014 Oct; 135(7):1543-52. PubMed ID: 24550147
[TBL] [Abstract] [Full Text] [Related]
13. Targeting wild-type and mutationally activated fgfr4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract] [Full Text] [Related]
14. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis.
Paulson V; Chandler G; Rakheja D; Galindo RL; Wilson K; Amatruda JF; Cameron S
Genes Chromosomes Cancer; 2011 Jun; 50(6):397-408. PubMed ID: 21412928
[TBL] [Abstract] [Full Text] [Related]
15. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Smalley KS; Flaherty KT
Future Oncol; 2009 Aug; 5(6):775-8. PubMed ID: 19663727
[TBL] [Abstract] [Full Text] [Related]
16. Bone mineral density deficits in pediatric patients treated for sarcoma.
Kaste SC; Ahn H; Liu T; Liu W; Krasin MJ; Hudson MM; Spunt SL
Pediatr Blood Cancer; 2008 May; 50(5):1032-8. PubMed ID: 17570705
[TBL] [Abstract] [Full Text] [Related]
17. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.
Morimoto Y; Ozaki T; Ouchida M; Umehara N; Ohata N; Yoshida A; Shimizu K; Inoue H
Cancer; 2003 Nov; 98(10):2245-50. PubMed ID: 14601095
[TBL] [Abstract] [Full Text] [Related]
